Isto Biologics was formed in 2016 when St. Louis-based Isto Technologies and Arteriocyte Medical Systems Inc. of Hopkinton, Massachusetts, joined forces under the Isto Holdings umbrella. Isto Biologics is focused on offering evidence-based solutions for bone regeneration and cell therapy to help improve patient outcomes. The companyÕs best-in-class product offerings include ArteriocyteÕs market-leading MAGELLAN¨ Autologous Platelet Separator and IstoÕs bone-growth and cell-therapy products including InQu¨ Bone Graft Extender & Substitute; Influx¨, a natural bone-graft material; and CellPoint¨, a concentrated bone marrow aspirate system.